| 查看: 521 | 回复: 1 | ||
| 本帖产生 1 个 翻译EPI ，点击这里进行查看 | ||
yaping221木虫 (正式写手)
|
[求助]
脂组学类翻译，谢谢！
|
|
|
In future personalized medicine enabled by lipidomics and metabolomic may expedite the mission of the right patients receiving the right drug at the right time and dose. Recently more potent drugs including monoclonal antibodies able to inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) and inflammatory pathways have been developed to improve current CAD care. However, these novel targeted treatments seem to be at present too expensive to be widely used among all CAD patients. Thus, sensitive biomarkers are needed for identification of patients most suitable for novel innovative treatments and the metabolomic and lipidomic biomarker candidates, in particular the ceramides, hold the potential to become clinically useful companion diagnostics of the future. |
回复此楼» 猜你喜欢
一志愿 江南大学 085602 化工专硕 338分求调剂
已经有14人回复
-
312求调剂
已经有3人回复
-
070300化学学硕311分求调剂
已经有13人回复
-
材料调剂
已经有9人回复
-
一志愿河北工业大学材料工程，初试344求专硕调剂
已经有4人回复
-
材料专硕322
已经有8人回复
-
一志愿211，化学学硕，310分，本科重点双非，求调剂
已经有13人回复
-
0703化学
已经有14人回复
-
调剂 一志愿吉林大学357分
已经有3人回复
-
化学调剂
已经有18人回复
genhunter
至尊木虫 (著名写手)
- 翻译EPI: 387
- 应助: 259 (大学生)
- 金币: 9757.4
- 散金: 10
- 红花: 60
- 帖子: 2484
- 在线: 1793小时
- 虫号: 2558361
- 注册: 2013-07-22
- 专业: 肿瘤化学药物治疗
【答案】应助回帖
★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★
yaping221: 金币+30, 翻译EPI+1 2016-03-06 09:30:31
yaping221: 金币+30, 翻译EPI+1 2016-03-06 09:30:31
|
In future personalized medicine enabled by lipidomics and metabolomic may expedite the mission of the right patients receiving the right drug at the right time and dose. Recently more potent drugs including monoclonal antibodies able to inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) and inflammatory pathways have been developed to improve current CAD care. 在未来基于脂类组学和代谢组学的个性化医学可以加快对合适病人的选择，以及选对药物，用药时间和剂量的决定。最近, 更为有效的药物，包括能抑制前蛋白转化酶枯草溶菌素 9型（PCSK9）和炎症通路的单克隆抗体已经开发，用于改善冠状动脉疾病的治疗。 However, these novel targeted treatments seem to be at present too expensive to be widely used among all CAD patients. Thus, sensitive biomarkers are needed for identification of patients most suitable for novel innovative treatments and the metabolomic and lipidomic biomarker candidates, in particular the ceramides, hold the potential to become clinically useful companion diagnostics of the future. 然而，在目前看来，这些新的靶向治疗比较昂贵，难以在所有冠状动脉疾病患者中广泛应用。因此，需要用灵敏的生物标志物去确定最合适新疗法以代谢和脂类生物标志物测定的的候选患者, 尤其是神经酰胺，未来有可能成为临床上有用的辅助诊断。 |
2楼2016-03-05 15:38:03
